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BACKGROUND: Randomized controlled trials (RCTs) have demonstrated that low-dose direct oral anticoagulants (DOACs), including 
rivaroxaban and apixaban, may help reduce the incidence of cancer-associated venous thromboembolism (VTE). METHODS: A cost-
utility analysis was performed from the health sector perspective using a Markov state-transition model in patients with cancer who are 
at intermediate-to-high risk for VTE. Transition probability, relative risk, cost, and utility inputs were obtained from a meta-analysis of the 
RCTs and relevant epidemiology studies. Differences in cost, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness 
ratio (ICER) per patient were calculated over a lifetime horizon. One-way, probabilistic, and scenario sensitivity analyses were con-
ducted. RESULTS: In patients with cancer at intermediate-to-high risk for VTE, treatment with low-dose DOAC thromboprophylaxis for 
6 months, compared with placebo, was associated with 32 per 1000 fewer VTE and 11 per 1000 more major bleeding episodes over a 
lifetime. The incremental cost and QALY increases were $1445 and 0.12, respectively, with an ICER of $11,947 per QALY gained. Key driv-
ers of ICER variations included the relative risks of VTE and bleeding as well as drug cost. This strategy was 94% cost effective at the 
threshold of $50,000 per QALY. The selection of patients with Khorana scores ≥3 yielded the greatest value, with an ICER of $5794 per 
QALY gained. CONCLUSIONS: Low-dose DOAC thromboprophylaxis for 6 months appears to be cost-effective in patients with cancer 
who are at intermediate-to-high risk for VTE. The implementation of this strategy in patients with Khorana scores ≥3 may lead to the 
highest cost-benefit ratio. Cancer 2020;126:1736-1748. © 2020 American Cancer Society. 
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INTRODUCTION
Cancer-associated thrombosis (CAT) is often the harbinger of complication or death in ambulatory patients with cancer.1,2  
Patients with venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), 
often experience a delay in cancer treatment as well as an increase in hospitalization rates and total health care cost.3 
Studies have shown that treatment of CAT with full-dose direct oral anticoagulant drugs (DOACs) produces simi-
lar clinical outcomes and quality-adjusted life-years (QALYs) at a lower to similar cost compared with low-molecular- 
weight heparin (LMWH).4-6 To our knowledge, no such economic analysis has been done in the preventive setting.
In the year 2019, 2 randomized controlled trials (RCTs) showed that thromboprophylaxis with low-dose DOACs, 
specifically apixaban and rivaroxaban, could help reduce the incidence of CAT compared with placebo.7,8 In contrast to 
prior studies that included patients with heterogeneous risk for VTE,9,10 those studies only selected patients with cancer 
who were at intermediate-to-high risk of VTE (approximately 9% by 6 months) based on the Khorana score risk stratifi-
cation.11 This patient selection strategy led to a higher absolute risk reduction of VTE than the absolute increase in major 
bleeding (MB) associated with low-dose DOAC prophylaxis.
Despite these promising results, it remains unclear whether a thromboprophylaxis strategy based on the Khorana 
score would affect QALYs in patients with cancer, whether it is cost effective from a health sector perspective, and which 
subgroup of patients would benefit the most from such an approach. In the current study, we performed a cost-utility 
analysis comparing low-dose DOAC versus placebo for the prevention of CAT in ambulatory patients with cancer. 
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Herein, we present our results for the overall popula-
tion with intermediate-to-high risk for CAT as well as a 
scenario analysis for patients determined to be high risk 
based on the Khorana score risk-stratification.
MATERIALS AND METHODS
Target Population and Setting
We built a Markov state-transition model to evaluate 
the cost utility of low-dose DOAC, including rivar-
oxaban and apixaban, versus placebo for the preven-
tion of CAT over a 40-year lifetime horizon. We used 
a hypothetical cohort ambulatory patients with can-
cer aged 60  years who were considered at intermedi-
ate-to-high risk for venous thromboembolism (VTE) 
(Khorana score ≥2) without absolute contraindications 
for thromboprophylaxis. The age was chosen based on 
the median age of participants in the clinical trials. To 
estimate the relative proportion of the most common 
cancer subtypes in this cohort, we pooled patients from 
both low-dose DOAC RCTs (see Supporting Table 1). 
We also considered subgroup analyses of patients at the 
highest risk for VTE (Khorana score ≥3) and those at 
intermediate risk (Khorana score 2).
Model Overview
The Markov model diagram is shown in Figure 1. The 
initial transition states for the model included on-proph-
ylaxis (prophylactic dose of DOAC), off-prophylaxis, 
first PE, first DVT, MB, and clinically relevant nonma-
jor bleeding (CRNMB). Patients who survived the first 
PE or DVT were transitioned into an on-treatment 
state (therapeutic dose of DOAC), which was linked to 
off-treatment, recurrent PE, recurrent DVT, MB, and 
CRNMB states. PE, DVT, MB, and CRNMB were tem-
porary states. Additional postcomplication states included 
postintracranial bleeding (post-ICH) after MB, chronic 
thromboembolic pulmonary hypertension (CTEPH) 
after PE, and post-thrombotic syndrome (PTS) after 
DVT. Finally, there were 3 self-absorbing death states for 
tracking purposes: PE-related death, MB-related death, 
and non-PE/non-MB–related (cancer) death. The cycle 
length was chosen to be 1 month as a clinically meaning-
ful time interval to capture potential transitions and apply 
the appropriate disutility weights from previous studies. 
The time horizon of 40  years was chosen as the maxi-
mum lifetime for individuals aged 60 years. Three percent 
yearly discounts for cost and quality were applied based 
on the US rates.12
Our Markov model made several assumptions: 
1) patients existed in mutually exclusive states; 2) patients 
who experienced a first VTE event would transition to 
treatment with a therapeutic-dose of DOAC and would 
remain on-treatment unless VTE, bleeding, death, or 
discontinuation occurred; 3) patients who experienced 
any bleeding while on prophylaxis would all transition 
off DOAC after 1 cycle because of low tolerance of 
adverse effects; 4) patients who experienced a recurrent 
VTE or CRNMB would return to the same anticoagu-
lant on-treatment state after 1 cycle unless death had 
occurred; 5) patients who experienced MB would transi-
tion to an off-treatment state after 1 cycle unless death had 
occurred; 6) patients who were still alive after 5 years had 
similar VTE and mortality rates as the general noncancer 
population; and 7) patients would suffer from bleeding 
complications and/or discontinue anticoagulant at a con-
stant rate unrelated to cancer remission or cure.
Model Input: Measurement of Effectiveness
To simulate the impact of thromboprophylaxis over a 
study period of 6 months, we first estimated the transition 
probabilities, risk ratios (RRs), and confidence intervals 
(CIs) for VTE, bleeding, discontinuation, and mortality 
outcomes in a meta-analysis of the AVERT (Apixaban for 
the Prevention of Venous Thromboembolism in Cancer 
Patients; clinicaltrials.gov identifier NCT02048865) and 
CASSINI (A Study to Evaluate the Efficacy and Safety of 
Rivaroxaban Venous Thromboembolism Prophylaxis in 
Ambulatory Cancer Participants; clnicaltrials.gov identi-
fier NCT02555878) RCTs.7,8,13 RR estimation was per-
formed using the Mantel-Haenszel random effects model 
(DerSimonian-Laird analysis).14 Transition probability for 
the pooled primary efficacy VTE outcome was reported 
for the overall follow-up and on-treatment study period. 
The probability for the pooled primary safety outcome 
was reported for the on-treatment study period only. The 
probability from on-prophylaxis to off-prophylaxis was 
estimated using the number of patients who permanently 
discontinued the study drug for any reason other than 
VTE, bleeding, or death, as reported in the supplemental 
material of the studies. Subgroup meta-analyses were per-
formed for patients with Khorana scores ≥3 and 2 after 
outcomes were obtained directly from the trial authors.13 
Because of the low case fatality associated with PE, MB, 
and ICH, pooled estimates were derived from 2 prophy-
laxis trials and 1 treatment trial (Hokusai-VTE Cancer).15
Model Input: Transition Probability Beyond 
Study Period
To estimate the time-varying transition probability for 
incident VTE beyond the first 6 months, we used data 
from a US epidemiology study16 rather than parametric 
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extrapolation from the RCTs because VTE incidence 
decreases significantly over time beyond initial cancer 
diagnosis and treatment. For the first 2 years, we esti-
mated the transition probability using the product of 
the cancer-specific VTE incident rate from the epide-
miology study and the proportion of cancer subtype 
from the RCTs (see Supporting Table 2). The rate was 
assumed to be constant between second and fifth years. 
After 5  years, we used the age-specific VTE incident 
rate from a UK epidemiology study of patients with-
out cancer.17 To estimate the probability for recurrent 
VTE while on-treatment, along with anticoagulant-
associated bleeding, discontinuation, and mortality, we 
used data reported in the DOAC arm of the Hokusai-
VTE Cancer RCT.15 The probability for recurrent VTE 
while off-treatment was estimated from the age-specific 
rates from a UK epidemiology study of patients with 
cancer.18 Finally, we estimated the probability for PTS 
and CTEPH from published studies.19,20
To estimate the time-varying transition probability 
for non-PE/non-MB mortality beyond the first 6 months, 
we used data from the Surveillance, Epidemiology, and End 
Results database.21 For the first 5 years, we estimated the 
probability using the product of the cancer-specific mor-
tality rate from the Surveillance, Epidemiology, and End 
Results data and the proportion of cancer subtype from the 
RCTs (see Supporting Table 3). After 5 years, we used the 
age-specific mortality rate from the US 2016 life-tables.22 
For patients with recurrent VTE, the mortality rate was 
estimated from the Hokusai-VTE Cancer study.
Model Input: Cost and Utility
Cost estimates were evaluated from a health sector per-
spective to include direct medical costs related to drugs 
Figure 1. The Markov state transition model is shown. AC indicates anticoagulant; CA, cancer-associated; CRNMB, clinically relevant 
nonmajor bleeding; CTEPH, chronic thromboembolic pulmonary hypertension; Discont, discontinuation; DVT, deep vein thrombosis; 
ICH, intracranial bleeding; MB, major bleeding; PE, pulmonary embolism; PH, pulmonary hypertension; PTS, post-thrombotic 
syndrome; rr, relative risk; tp, transition probability.
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and complications. Unit costs for prophylactic doses 
of rivaroxaban 10 mg ($14.93), apixaban 2.5 mg ($7.40), 
and therapeutic doses of edoxaban 60 mg ($12.12), and 
enoxaparin 100 mg ($15.00) were based on the whole-
sale acquisition cost from the Red Book.23 Monthly costs 
(each cycle) were derived from 30-day prescriptions of the 
drugs at the labeled dosing frequency (daily for rivaroxa-
ban and edoxaban, twice daily for apixaban). Additional 
drug cost analysis was performed using the Federal 
Supply Schedule as a sensitivity analysis. Adverse event 
costs (each cycle) for initial and recurrent VTE events as 
well as bleeding episodes were obtained from the report 
by Preblick et al, in which the cost-per-stay estimates 
were derived from the Premier Hospital Database and a 
post-hoc analysis of the DOAC arm of the Hokusai-VTE 
study.24 For postcomplication states, the monthly cost 
(each cycle) was estimated from the appropriate publi-
cations for post-ICH, PTS, and CTEPH.25-27 All cost 
estimates were inflated to May 2019 US dollars using 
the US Consumer Price Index for all urban consumers’ 
medical care.28
Utility weights and CI ranges between 0 and 1 were 
derived from published literature. We first estimated the 
baseline utility weight for patients with cancer as the 
product of cancer-specific utility weight from various 
studies and the proportion of cancer subtype from the 
RCTs (see Supporting Table 4).29-33 We then calculated 
the disutility from general medical patients with VTE, 
bleeding, ICH, PTS, and CTEPH and subtracted the 
disutility from the baseline utility weight to determine 
the adjusted weight for each outcome state.24,34-36 For the 
primary utility measures of VTE and bleeding, we used 
the data published by Hogg et al, who that used a stan-
dard gamble method from 216 ambulatory patients with 
a history of DVT or PE.34
Base-Case and Sensitivity Analyses
For the base-case analysis, the cumulative cost and QALYs 
were estimated for each treatment over a lifetime time 
horizon. The incremental cost-effectiveness ratio (ICER) 
was calculated as the difference in cost over the differ-
ence in QALYs. Half-cycle correction was not performed 
given the short cycle length of 1 month. To highlight the 
model’s calibration performance, we also reported clinical 
events at a time horizon of 6 months to emulate the out-
comes reporting from the RCTs.
We performed one-way deterministic sensitivity 
analyses. The upper and lower bounds of the 95% CIs 
were used if such data were available the from litera-
ture (Table 1).15-17,19-27,34-36 Otherwise, the variations 
were assumed to be ±20% from the mean value. We 
performed probabilistic sensitivity analysis using 
Monte Carlo simulation over 1000 times to generate 
the cost-effectiveness plane and the cost-effectiveness 
acceptability curve. The distributions assumed for the 
input parameters were γ (cost), β (utility weights and 
transition probability), and log-normal (RR) (Table 1). 
The standard errors were derived from the 95% CIs, 
and α/β parameters were estimated using the method 
of moments.
Finally, we performed several scenario and sensitiv-
ity analyses by varying the duration of intervention (6 
vs 12  months), the treatment effect estimate (on-treat-
ment vs intention-to-treat period), and the risk profile of 
the population (high risk vs intermediate risk). All data 
analyses in this study were performed in Microsoft Excel 
for Mac 16.17. We adhered to the Consolidated Health 
Economic Evaluation Reporting Standards statement in 
presenting this analysis.37
RESULTS
Evidence Synthesis on Effectiveness Measures
The measurement of effectiveness for low-dose DOAC 
intervention based on the meta-analysis of the AVERT and 
CASSINI RCTs are shown in Table 2. For the primary 
efficacy outcome of first VTE occurrence by 6 months, 
low-dose DOAC prophylaxis was associated with an RR 
of 0.56 (95% CI, 0.35-0.89) for VTE. A higher risk reduc-
tion with an RR of 0.30 (95% CI, 0.16-0.53) was found 
for the on-treatment only study period. For the safety 
outcomes by 6  months, the intervention was associated 
with an RR of 1.96 (95% CI, 0.80-4.82) for MB and an 
RR of 1.28 (95% CI, 0.74-2.20) for CRNMB. Both the 
intervention arm and the placebo arm had similar rates 
of drug discontinuation unrelated to primary outcomes, 
with an RR of 1.00 (95% CI, 0.84-1.19). The 2 RCTs 
had moderate heterogeneity in the mortality outcome 
reporting and a pooled RR of 0.98 (95% CI, 0.67-1.43); 
however, this estimate was not used because there is not a 
biologic rationale for the drug intervention to influence 
non-PE/non-MB–related mortality. We also performed 
a meta-analysis of the above outcomes for subgroups 
according to Khorana score. In patients with Khorana 
scores ≥3, low-dose DOAC prophylaxis was associated 
with an RR of 0.47 (95% CI, 0.25-0.89) for VTE and an 
RR of 1.60 (95% CI, 0.42-6.01) for MB; in those with 
Khorana scores of 2, low-dose DOAC prophylaxis had an 
RR of 0.60 (95% CI, 0.30-1.19) for VTE and an RR of 
1.91 (95% CI, 0.56-6.53) for MB. The proportions of 
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TABLE 1. Parameter Inputs With a Cycle Length of 1 Month
Parameter Reference Base Case Lower Upper Distribution
Costs (c), $a          
cDOAC_ppx   446 357 535 γ
Apixaban 2.5 mg twice daily Red Book 201923 444      
Rivaroxaban 10 mg daily Red Book 201923 448      
cEdoxaban_rx 30-60 mg daily Red Book 201923 364 291 436 γ
cEnoxaparin_rx 100 mg daily Red Book 201923 450 360 540 γ
cPE1 (first) Preblick 201524 16,903 13,522 20,283 γ
cDVT1 (first) Preblick 201524 9766 7813 11,720 γ
cPEr (recurrent) Preblick 201524 18,705 14,964 22,446 γ
cDVTr (recurrent) Preblick 201524 8878 7103 10,654 γ
cMB Preblick 201524 19,469 15,575 23,363 γ
cCRNMB Preblick 201524 4880 3904 5856 γ
cPost-ICH Lee 200725 1129 903 1355 γ
cPTS Caprini 200326 235 188 282 γ
cCTEPH Kirson 201127 6814 5451 8177 γ
Utility weights (u)          
uBaseb see Supporting Table 4 0.74 0.59 0.89 β
uPE Hogg 201334 −0.25 −0.55 −0.09 β
uDVT Hogg 201334 −0.19 −0.45 −0.06 β
uMB Hogg 201334 −0.09 −0.27 0.00 β
uCRNMB Preblick 201524 −0.35 −0.85 −0.14 β
uICH Lenert & Soetikno 199735 −0.40 −0.98 −0.00 β
uPTS Lenert & Soetikno 199735 −0.05 −0.21 −0.00 β
uCTEPH Ghofrani 201336 −0.34 −0.83 −0.00 β
Transition probabilities (tp), %          
tpPE1_1-6moc see Table 2 0.82 0.66 0.99 β
tpDVT1_1-6moc see Table 2  0.75 0.60 0.90 β
tpMB1c see Table 2 0.17 0.14 0.21 β
tpCRNMB1c see Table 2 0.55 0.44 0.66 β
tpDiscont1c see Table 2 5.36 4.29 6.43 β
tpCA1_death_1-12moc see Table 2 3.18 2.54 3.81 β
tpPE1_7-12mod see Supporting Table 2 0.29 0.23 0.35 β
tpDVT1_7-12mod see Supporting Table 2 0.26 0.21 0.32 β
tpPE1_13-60mod see Supporting Table 2 0.07 0.05 0.08 β
tpDVT1_13-60mod see Supporting Table 2 0.06 0.05 0.07 β
tpPE1_60yod Martinez 201417 0.01 0.01 0.01 β
tpPE1_70yod Martinez 201417 0.01 0.01 0.02 β
tpPE1_80yod Martinez 201417 0.02 0.02 0.03 β
tpPE1_90yod Martinez 201417 0.03 0.02 0.04 β
tpDVT1_60yod Martinez 201417 0.01 0.01 0.01 β
tpDVT1_70yod Martinez 201417 0.01 0.01 0.02 β
tpDVT1_80yod Martinez 201417 0.02 0.02 0.03 β
tpDVT1_90yod Martinez 201417 0.03 0.02 0.03 β
tpCA1_death_13-24moe SEER Program 201821 1.96 1.57 2.36 β
tpCA1_death_25-36moe SEER Program 201821 1.12 0.90 1.35 β
tpCA1_death_37-48moe SEER Program 201821 0.73 0.58 0.87 β
tpCA1_death_49-60moe SEER Program 201821 0.58 0.46 0.69 β
tpCA1_death_60+moe Arias 201922 Variable Variable Variable β
tpPE2 Raskob 201815 0.44 0.35 0.53 β
tpDVT2 Raskob 201815 0.23 0.18 0.28 β
tpMB2 Raskob 201815 0.59 0.47 0.71 β
tpCRNMB2 Raskob 201815 1.30 1.04 1.56 β
tpDiscont2 Raskob 201815 1.58 1.26 1.90 β
Cost Utility Analysis for Cancer VTE/Li et al
1741Cancer  April 15, 2020
patients who died from PE or MB or who developed ICH 
were too small and heterogeneous for a meaningful meta- 
analysis. Therefore, we included data from both prophy-
laxis RCTs and the treatment RCT for pooled estimation. 
On the basis of this analysis, PE and MB case fatalities were 
13.21% (n = 14) and 3.85% (n = 3), respectively, and 
ICH occurred in 10.26% of patients with MB (n = 8).
Base-Case Cost-Effectiveness Analysis
In the base-case analysis over lifetime (Table 3), low-dose 
DOAC thromboprophylaxis for 6 months was associated 
with 20 fewer PEs, 12 fewer DVTs, 11 more MB events, 
and 21 more CRNMB events per 1000 patients. The 
distribution of ICH, CTEPH, PTS, and event-related 
deaths were similar between intervention and placebo 
arms. A similar pattern of clinical outcomes was observed 
over 6 months and over 5 years (see Supporting Table 5). 
The absolute differences in all clinical outcomes, includ-
ing overall VTE, PE, DVT, MB, CRNMB, and mortality, 
were all within the 95% CI of previously reported out-
comes from the meta-analysis at 6 months.13 Minor vari-
ations in outcomes were likely driven by the inclusion of a 
drug nonadherence/discontinuation factor in the Markov 
model, which led to small attenuations of the absolute 
risk reductions of the primary outcomes. Over a lifetime, 
the intervention group had a mean total cost of $9899 
per person, 6.51 life-years, and 4.79 QALYs. The placebo 
group had a mean total cost of $8454 per person, 6.34 
life-years, and 4.67 QALYs. Low-dose DOAC prophy-
laxis was associated with an incremental cost increase of 
$1445, an incremental QALY increase of 0.12, and an 
ICER of $11,947 per QALY.
In one-way sensitivity analyses (Fig. 2), variations in 
the relative risks of PE, DVT, and MB along with the 
Parameter Reference Base Case Lower Upper Distribution
tpCA2_death Raskob 201815 3.95 3.16 4.74 β
tpPE3_60yof Cohen 201718 0.44 0.36 0.54 β
tpPE3_70yof Cohen 201718 0.47 0.37 0.57 β
tpPE3_80yof Cohen 201718 0.48 0.35 0.40 β
tpPE3_90yoff Cohen 201718 0.57 0.16 1.46 β
tpDVT3_60yof Cohen 201718 0.40 0.32 0.40 β
tpDVT3_70yof Cohen 201718 0.38 0.30 0.47 β
tpDVT3_80yof Cohen 201718 0.33 0.22 0.47 β
tpDVT3_90yof Cohen 201718 0.43 0.09 1.25 β
tpPE_death (pooled PE fatality %)c see Table 2 13.21 10.57 15.85 β
tpMB_death (pooled MB fatality %)c see Table 2 3.85 3.08 4.62 β
tpMB_ICH (pooled MB to ICH %)c see Table 2 10.26 8.21 12.31 β
tpDVT_PTS Kahn 201420 12.70 10.16 15.24 β
tpPE_CTEPH Ende-Verhaar 201719 2.80 1.50 4.10 β
Relative risk (rr)          
rrPE1c see Table 2 0.49 0.23 1.04 Log-normal
rrDVT1c see Table 2 0.64 0.37 1.11 Log-normal
rrMB1c see Table 2 1.96 0.80 4.82 Log-normal
rrCRNMB1c see Table 2 1.28 0.74 2.20 Log-normal
rrDiscont1c see Table 2 1.00 0.84 1.19 Log-normal
Discounting          
oDR Federal Reserve 201812 0.03      
cDR Federal Reserve 201812 0.03      
Abbreviations: AC indicates anticoagulant; CA, cancer-associated; cDR, cost discount rate; CRNMB, clinically relevant nonmajor bleeding; CTEPH, chronic 
thromboembolic pulmonary hypertension; Discont, discontinuation; DVT, deep vein thrombosis; ICH, intracranial bleeding; MB, major bleeding; oDR, outcome 
discount rate; PE, pulmonary embolism; PH, pulmonary hypertension; ppx, prophylaxis; PTS, post-thrombotic syndrome; yo, years old.
aAll cost estimates were inflated to 2019 US dollars using the US Consumer Price Index for all urban consumers’ medical care.
bBaseline utility weight was estimated as the sum of the product of the cancer-specific utility weight and the relative proportion of cancer subtypes from 2 ran-
domized controlled trials (RCTs) (see Supporting Table 4); adverse event utility weights were estimated by subtraction of the disutility from the baseline weight.
cThe transition probability and relative risk for the first 6 months were derived from the meta-analysis of the 2 RCTs, as shown in Table 2.
dThe incidence of venous thromboembolism (VTE) beyond first 6 months was estimated as the sum of the product of the cancer-specific VTE rate (Chew 200616) 
and the relative proportion of the cancer subtype from the 2 RCTs; the incidence of VTE after 60 months (5 years) was estimated using the age-specific VTE inci-
dence rate in the noncancer population (Martinez 201417).
eThe incidence of mortality beyond first 12 months was estimated as the sum of the product of the cancer-specific mortality rate (Surveillance, Epidemiology, and 
End Results Program 201821) and the relative proportion of cancer subtype from 2 randomized RCTs; the incidence of mortality after 60 months was estimated 
using US life-tables (Arias 201922).
fThe incidence of VTE recurrence when off treatment was estimated using the age-specific VTE recurrence rate in the cancer VTE population (Cohen 201718).
TABLE 1. Continued
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TABLE 2. Pooled Measurement of Effectiveness From Direct Oral Anticoagulant Thromboprophylaxis Trials
Variable
No./Total No. (%)
RR [95% CI]DOAC Placebo
VTE outcomes on PPX      
First VTE by 6 mo 37/711 (5.20) 65/704 (9.23) 0.56 [0.35-0.89]
PE 17/711 (2.39) 34/704 (4.83) 0.49 [0.23-1.04]
AVERT 5/291 (1.72) 16/283 (5.65)  
CASSINI 12/420 (2.86) 18/421 (4.28)  
DVT 20/711 (2.81) 31/704 (4.40) 0.64 [0.37-1.11]
AVERT 7/291 (2.41) 12/283 (4.24)  
CASSINI 13/420 (3.10) 19/421 (4.51)  
First VTE during on-treatment period 
(sensitivity)
14/711 (1.97) 47/704 (6.68) 0.30 [0.16-0.53]
AVERT 3/291 (1.03) 20/704 (2.84)  
CASSINI 11/420 (2.62) 27/421 (6.41)  
Bleeding outcomes on PPX      
MB during on-treatment period 14/693 (2.02) 7/679 (1.03) 1.96 [0.80-4.82]
AVERT 6/288 (2.08) 3/275 (1.09)  
CASSINI 8/405 (1.98) 4/404 (0.99)  
CRNMB during on-treatment period 29/693 (4.18) 22/679 (3.24) 1.28 [0.74-2.20]
AVERT 18/288 (6.25) 14/275 (5.09)  
CASSINI 11/405 (2.72) 8/404 (1.98)  
Nonadherence/intolerance on PPX      
Drug discontinuation unrelated to  
death/VTE/bleed
195/693 (28.14) 191/679 (28.13) 1.00 [0.84-1.19]
AVERT 88/288 (31.27) 76/275 (29.68)  
CASSINI 107/405 (26.42) 115/404 (28.47)  
Mortality on PPX      
Non-PE/non-MB mortality by 6 mo 117/711 (16.46) 124/704 (17.61) 0.98 [0.67-1.43]a 
AVERT 35/291 (12.03) 27/283 (9.54)  
CASSINI 82/420 (19.52) 97/421 (23.04)  
Subgroup analysis on PPX (Khorana  
score ≥3)
     
First VTE by 6 mo 13/239 (5.44) 25/216 (11.57) 0.47 [0.25-0.89]
AVERT 6/105 (5.71) 12/93 (12.90)  
CASSINI 7/134 (5.22) 13/123 (10.57)  
First VTE during on-treatment period 
(sensitivity)
7/239 (2.93) 17/216 (7.87) 0.38 [0.14-1.07]
AVERT 2/105 (1.90) 9/93 (9.68)  
CASSINI 5/134 (3.73) 8/123 (6.50)  
MB during on-treatment period 6/233 (2.58) 3/211 (1.42) 1.60 [0.42-6.01]
AVERT 2/105 (1.90) 0/90 (0.00)  
CASSINI 4/128 (3.13) 3/121 (2.48)  
Subgroup analysis on PPX (Khorana  
score 2)
     
First VTE by 6 mo 24/467 (5.14) 40/485 (8.25) 0.60 [0.30-1.19]
AVERT 6/186 (3.23) 16/190 (8.42)  
CASSINI 18/281 (6.41) 24/295 (8.14)  
First VTE during on-treatment period 
(sensitivity)
7/467 (1.50) 30/485 (6.19) 0.24 [0.08-0.73]
AVERT 1/186 (0.54) 11/190 (5.79)  
CASSINI 6/281 (2.14) 19/295 (6.44)  
MB during on-treatment period 8/456 (1.75) 4/465 (0.86) 1.91 [0.56-6.53]
AVERT 4/183 (2.19) 3/185 (1.62)  
CASSINI 4/273 (1.47) 1/280 (0.36)  
Variable
Combined DOAC and Placebo
RR [95% CI]No./Total No. Percentage
Pooled % estimates for PPX and RXb      
PE case fatality 14/106 13.21 NA
AVERT 0/21 0.00  
CASSINI 4/30 13.33  
Hokusai-VTE cancer study 10/55 18.18  
MB case fatality 3/78 3.85 NA
AVERT 0/9 0.00  
CASSINI 1/12 8.33  
Hokusai-VTE cancer study 2/57 3.51  
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cost associated with low-dose DOAC prophylaxis led to 
the largest differences in the ICER. In probabilistic sen-
sitivity analysis (Fig. 3, Table 3), low-dose DOAC pro-
phylaxis was associated with an incremental cost increase 
of $1537, an incremental QALY increase of 0.11, and an 
ICER of $14,330 per QALY. As shown in the cost effec-
tiveness acceptability curve (Fig. 4), this strategy would be 
cost effective 94% of the time if we assume a ceiling ICER 
of $50,000 per QALY.
Sensitivity and Scenario Analyses
We performed several sensitivity analyses to test the 
robustness of the model under various assumptions. First, 
we substituted the transition probability and RR of VTE 
occurrence with the pooled estimates derived from the 
as-treated study period instead of the overall intention-
to-treat follow-up (Table 4). Although the intention-to-
treat estimates preserve the randomization and generally 
represent unconfounded effects associated with the inter-
vention, the as-treated estimates are more realistic because 
our Markov model accounts for unintended discontinua-
tion of study drugs. Compared with the primary analysis, 
low-dose DOAC prophylaxis in this analysis was associ-
ated with a similar incremental cost increase, a greater 
incremental QALY increase (0.14 vs 0.12 QALYs), and 
an ICER of $9896 per QALY. Second, we examined the 
effect of assigning patients to 12 months of prophylaxis 
instead of 6 months (Table 5). Compared with the primary 
analysis, low-dose DOAC prophylaxis in this scenario was 
associated with a greater incremental cost increase ($2410 
vs $1445), a greater incremental QALY increase (0.15 vs 
0.12), and an ICER of $16,389 per QALY. Third, we 
examined how the extrapolation of mortality rate based 
on the year-5 cancer mortality rate instead of US life- 
tables would affect the overall outcome. In this sensitivity 
TABLE 3. Cost-Utility Analysis Outcomes
Outcome
No. of Events per 1000 Patients  
Over Lifetime
Low-Dose DOAC Placebo
Total PE 73 93
First event 62 80
Recurrent event 11 13
Total DVT 69 81
First event 62 73






PE-related death 10 12
MB-related death 7 7
Non-PE/non-MB death 982 980
Deterministic outcomes    
Cost    
Total cost $9899 $8454







ICER (per QALY)$ $11,947
Probabilistic outcomes    
Cost    
Total cost $10,007 $8470







ICER (per QALY) $14,330
Abbreviations: CRNMB, clinically relevant nonmajor bleeding; CTEPH, chronic 
thromboembolic pulmonary hypertension; DOAC, direct oral anticoagulant; 
DVT, deep vein thrombosis; ICER, incremental cost-effectiveness ratio; ICH, 
intracranial hemorrhage; LY, life-year; MB, major bleeding; PE, pulmonary 
embolism; PTS, post-thrombotic syndrome; QALY, quality-adjusted life-year.
Variable
Combined DOAC and Placebo
RR [95% CI]No./Total No. Percentage
MB to ICH 8/78 10.26 NA
AVERT 0/9 0.00  
CASSINI 2/12 16.67  
Hokusai-VTE cancer study 6/57 10.53  
Abbreviations: AVERT, Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients (clinicaltrials.gov identifier NCT02048865); CASSINI, A 
Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism Prophylaxis in Ambulatory Cancer Participants (clnicaltrials.gov identifier 
NCT02555878); CRNMB, clinically relevant nonmajor bleeding; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; MB, major bleeding; NA, not applica-
ble; PE,: pulmonary embolism; PPX, prophylaxis; RX, treatment; VTE, venous thromboembolism.
aEstimates for the RR of mortality were not used because of the lack of a biologic rationale that DOAC improves survival. As the most conservative approach, only 
pooled incidence estimate from the placebo arms was used for the transition probability of cancer-associated death during the first 12 months.
bPooled estimates were derived from multiple DOAC trials because of the small event rate in each study arm for individual trials.
TABLE 2. Continued
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analysis, the incremental cost difference was similar, but 
the incremental QALY difference was smaller between the 
DOAC and placebo arms, and the resulting ICER was 
higher at $15,602 per QALY (Table 6). Finally, we assessed 
how differential negotiated drug-acquisition cost would 
affect our outcomes by using the Federal Supply Schedule 
drug pricing instead of the Red Book commercial pric-
ing. In this sensitivity analysis, the lower acqui sition drug 
cost for apixaban translated into a lower incremental cost 
difference of $518, an unchanged incremental QALY dif-
ference for the 2 arms, and an ICER of $4283 per QALY 
gained over a lifetime (Table 7).
Stratified Analysis: Highest Risk Versus 
Intermediate Risk
To better characterize the heterogeneous benefits of 
low-dose DOAC prophylaxis in CAT prevention, we 
explored the cost effectiveness of the intervention after 
stratification by the Khorana score. As expected, selec-
tion of the higher risk group yielded more favorable 
cost-effectiveness values. Patients who had the highest 
risk of thrombosis with Khorana scores ≥3 (Table 8) had 
an incremental cost increase of $1103, an incremental 
Figure 2. A one-way sensitivity analysis (Tornado diagram) is illustrated. DOAC indicates direct oral anticoagulant; DVT, deep vein 
thrombosis; MB, major bleeding; PE, pulmonary embolism.
Figure 3. A probabilistic sensitivity analysis is illustrated.
Figure 4. A cost-effectiveness acceptability curve is shown. 
DOAC indicates direct oral anticoagulant.
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QALY increase of 0.19, and an ICER of $5794 per 
QALY. In contrast, those who had an intermediate risk 
of thrombosis with a Khorana score of 2 (Table 9) had 
an incremental cost increase of $1527, an incremental 
QALY increase of 0.11, and an ICER of $15,118 per 
QALY.
DISCUSSION
In on our cost-utility analysis using the Markov model, 
we found that low-dose DOAC (rivaroxaban or apixa-
ban) thromboprophylaxis for 6 months was a cost-effec-
tive strategy for the prevention of CAT in patients with 
cancer who were at intermediate-to-high risk for CAT 
in the United States. The ICER was considered cost 
effective 94% of the time using the traditional $50,000 
per QALY value threshold. Although the exact “thresh-
old” used in cost-effectiveness analyses remains a matter 
of debate, the $50,000 benchmark serves well as a sug-
gested lower boundary.38 The cost-effectiveness values 
were particularly high for patients with the highest-risk 
for VTE (Khorana scores ≥3). As the first formal eco-
nomic evaluation on the use of low-dose DOACs to pre-
vent CAT, we believe that findings from the current study 
offer new insight into appropriate patient selection based 
on society’s willingness-to-pay threshold, which, in turn, 
can help health systems and payers decide whether to 
implement such a thromboprophylaxis intervention.
CAT is a common complication associated with 
anticancer therapy; however, controversies exist on the 
need, duration, and choice of thromboprophylaxis.39 As 
shown in our Markov model, appropriate prevention of 
VTE could help reduce future VTE treatment-associated 
costs and complications, even if it does not directly 
reduce cancer-associated mortality. The success of a pro-
phylactic strategy depends both on the baseline rate of 
TABLE 4. Sensitivity Analysis #1: Outcomes Based 
on On-Treatment (As-Treated) Instead of Overall 
Follow-Up (Intention to Treat) Transition Probability 
and Relative Risk for VTE
Outcome Low-Dose DOAC Placebo
Deterministic outcome    
Cost    
Total cost $9448 $8038







ICER (per QALY) $9896
Abbreviations: DOAC, direct oral anticoagulant; ICER, incremental cost- 
effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year.
TABLE 5. Sensitivity Analysis #2: Outcomes Based 
on 12-Months Instead of 6-Month Duration of Drug 
Prophylaxis
Outcome Low-Dose DOAC Placebo
Deterministic outcome    
Cost    
Total cost $10,864 $8454







ICER (per QALY) $16,389
Abbreviations: DOAC, direct oral anticoagulant; ICER, incremental cost- 
effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year.
TABLE 6. Sensitivity Analysis #3: Outcomes Based 
on Constant Cancer Mortality Rate From Year 5 and 
Beyond Instead of Life-Table Extrapolation
Outcome Low-Dose DOAC Placebo
Deterministic outcome    
Cost    
Total cost $8874 $7466







ICER (per QALY) $15,602
Abbreviations: DOAC, direct oral anticoagulant; ICER, incremental cost- 
effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year.
TABLE 7. Sensitivity Analysis #4: Outcomes Based 
on Drug Pricing Estimates from the Federal Supply 
Schedule Instead of the Red Book
Outcome Low-Dose DOAC Placebo
Deterministic outcome    
Cost    
Total cost $8798 $8280







ICER (per QALY) $4283
Abbreviations: DOAC, direct oral anticoagulant; ICER, incremental cost- 
effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year.
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VTE occurrence and on the relative risk reduction asso-
ciated with the intervention. In older studies that com-
pared LMWH versus placebo for the prevention of CAT 
(Prevention of Venous and Arterial Thromboembolism, 
in Cancer Patients Undergoing Chemotherapy, With a 
Low Molecular Weight Heparin [PROTECHT; Clinical-
Trials.gov Identifier: NCT00951574], Evaluation of 
AVE5026 in the Prevention of Venous Thromboembolism 
in Cancer Patients Undergoing Chemotherapy [SAVE-
ONCO; clinicaltrials.gov identifier NCT00694382]), 
the baseline risk of VTE was only 3% to 4% by 
6 months.40,41 The 2 trials included in the current study 
(AVERT and CASSINI) enrolled patients at interme-
diate-to-high risk for VTE (Khorana score ≥2), which 
resulted in VTE rates of approximately 9% by 6 months 
in the placebo groups.7,8 The subgroup of patients with 
Khorana scores ≥3 reached rates as high as 12%. Because 
the risk of VTE is highest at the time of cancer diagnosis 
and plateaus over time,42 a prophylactic strategy focusing 
on the initial high-risk period may be the most benefi-
cial approach. On the basis of our various sensitivity and 
scenario analyses, we believe that a health system–wide 
implementation of limited duration (6 months), low-dose 
DOAC thromboprophylaxis for patients with Khorana 
scores ≥3 would lead to the highest incremental qual-
ity gained at the lowest incremental cost from a policy 
implication standpoint. Finally, it is important to con-
sider both the incremental QALY in the context of lower 
baseline quality-of-life associated with cancer symptoms 
as well as any incremental cost in light of the very expen-
sive nature of current cancer treatment.43 Future studies 
focusing on quality-of-life measurement associated with 
VTE and bleeding among patients with cancer who are 
DOACs are needed.
There are several strengths to our current study. 
The study benefited from a combination of pooled 
efficacy and safety data from primary RCTs for the first 
6  months during intervention and from epidemiology 
studies beyond 6  months during the follow-up period. 
The generalizability of the findings was also strengthened 
by the concordance of various sensitivity and subgroup 
analyses. The key drivers found in our one-way sensi-
tivity analysis were consistent with our expectation that 
either more precise estimation of the primary efficacy 
and safety outcomes or of the drug cost would have the 
greatest impact on the ICER estimation. Finally, we per-
formed our cost-utility analysis over a lifetime horizon, 
in accordance with the Consolidated Health Economic 
Evaluation Reporting Standards guideline, to reflect the 
long-term consequences of a relatively short (6-month) 
preventive intervention. Economic evaluations based on 
RCTs often have truncated time horizons because of the 
impracticality of long-term follow-up.44 Nonetheless, 
early differences in key outcomes such as mortality should 
be evaluated over a lifetime for the most accurate estima-
tion of value. To address this issue, we modeled survival 
using cancer mortality rates and life-table rates uniformly 
in both intervention and placebo cohorts. The similarity 
in clinical 6-month, 5-year, and lifetime outcomes suggest 
that the differences in QALYs (see Supporting Table 5) 
were driven mostly by early preventive effects.
There are also inherent limitations with our study. 
An assumption worthy of highlighting is that patients 
would continue the same anticoagulant treatment indefi-
nitely unless they discontinued the drug at a prespecified 
discontinuation rate. In reality, some patients (eg, those 
who experience VTE but are alive and cancer-free after 
1-2  years) would likely stop anticoagulant treatment. 
TABLE 8. Subgroup Analysis #1: Outcomes Based 
on the High-Risk Subgroup Patients Only (Khorana 
Score ≥3)
Outcome Low-Dose DOAC Placebo
Deterministic outcome    
Cost    
Total cost $9987 $8884







ICER (per QALY) $5794
Abbreviations: DOAC, direct oral anticoagulant; ICER, incremental cost- 
effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year.
TABLE 9. Subgroup Analysis #2: Outcomes Based 
on the Intermediate-Risk Subgroup Patients Only 
(Khorana Score 2)
Outcome Low-Dose DOAC Placebo
Deterministic outcome    
Cost    
Total cost $9334 $7807







ICER (per QALY) $15,118
Abbreviations: DOAC, direct oral anticoagulant; ICER, incremental cost- 
effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year.
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Those with upper extremity or catheter-associated 
DVTs also tend to have a shorter duration of treatment. 
Furthermore, patients often switch the type of anticoag-
ulant during treatment. Such specific scenarios cannot 
be fully addressed without a patient-level simulation 
model with tremendous complexity. Another limitation 
involves the extrapolation of efficacy and safety data be-
yond 6 months. To mitigate potential errors, we applied 
the same rates beyond 6 months to both intervention and 
placebo arms and conducted sensitivity analyses to show 
that these later rates had little effect on the ICER. Other 
limitations include the extrapolation of cost and utility 
data from patients without to patients with cancer. We 
derived the direct medical cost from a post-hoc analysis 
of a DOAC trial for medical patients with VTE and did 
not consider direct nonmedical cost, indirect cost, or in-
dividual coupons or cost-assistance programs. We also 
derived the utility weights from a study of general medi-
cal patients with VTE. Because the standard of care was 
LMWH or warfarin in these older studies, future work 
dedicated to patients with VTE receiving DOAC prophy-
laxis are needed to ensure generalizability. Finally, we only 
performed subgroup analysis for patients with risk strat-
ifications of VTE by Khorana score. Other subgroups, 
such as patients with different types of cancer, may ben-
efit differently from thromboprophylaxis and would 
require dedicated analysis in the future.
In conclusion, thromboprophylaxis with low-dose 
DOAC (rivaroxaban or apixaban) for 6 months appears 
to be a cost-effective strategy for the prevention of CAT 
in the United States. Future research should focus on a 
better understanding of the significance of these adverse 
events on longer term quality of life and their impact on 
delays in anticancer treatment.
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